## ELBIT MEDICAL IMAGING LTD Form 425 September 12, 2005

Filed by Elbit Medical Imaging Ltd.
Pursuant to Rule 425 under the
Securities Act of 1933 and deemed filed
pursuant to Rule 14a-12 under the
Securities Exchange Act of 1934
Subject Company: Elscint Ltd.
Commission File No.: 001-08781

The following is a press release disseminated by Elbit Medical Imaging Ltd. on September 12, 2005:

FOR IMMEDIATE RELEASE

#### ELBIT MEDICAL IMAGING LTD. ANNOUNCES

#### SECOND QUARTER 2005 RESULTS

Tel Aviv, Israel - September 12, 2005 - Elbit Medical Imaging Ltd. (NASDAQ: EMITF) ("EMI" or the "Company") today announced its consolidated results for the three and six-month periods ended June 30, 2005.

Net loss for the second quarter of 2005 totaled NIS 30.8 million (US \$6.7 million), compared with a net loss of NIS 54.4 million in the corresponding period of 2004.

Revenues for the second quarter of 2005 totaled NIS 143.9 million (US \$31.5 million), compared with revenues of NIS 172.4 million in the corresponding period of 2004.

Commentary for the Second Quarter:

Mr. Shimon Yitzhaki, President of Elbit Medical Imaging commented: "The results of the second quarter of 2005 do not reflect EMI's current business position as they include expenses incurred in respect of the sale of shopping and entertainment centers to the Klepierre group, but do not record the capital gains expected from such transaction.

"The results also include NIS 22.6 million (US \$4.9 million) due to a provision for a neither recurring nor cash flow entailing impairment loss expected on EMI's investment in Vcon Telecommunication Ltd., and a provision for a loss that may result from a decrease in EMI's shareholding in Elscint Ltd., a subsidiary of the Company (NYSE: ELT) ("Elscint"), assuming realization of Elscint's employees stock.

"In addition, EMI's research and development expenses increased in the second quarter of 2005 due to an acceleration in R&D efforts by EMI's subsidiary, InSightec Image Guided Treatment Ltd. ("InSightec"), for several potential applications."

Finally, concluded Mr. Yitzhaki: "EMI's proposed merger with Elscint is intended to enable the merging companies to exploit opportunities that were previously unavailable to either company independently, and to reduce operational costs."

The Chairman of the Board Mr. Mordechay Zisser, commented: "The recent Klepierre Agreement together with the previous sales agreements during the last year, in total aggregate amount of US \$1 billion further establish EMI's position as the regional industry leader in development and construction of shopping and

entertainment centers, and demonstrate the success of our strategy of co-operation with large European bodies in various areas of operations. Moreover, the Klepierre transactions have enabled EMI to

accelerate its development and construction of additional shopping and entertainment centers in Europe. The EMI results for the second quarter of 2005 do not reflect the substantial profit from the transactions with Klepierre that the Company expects to record later this year and in 2006."

The breakdown of revenue by sector of activity is presented in the following table (in NIS thousands):

	2005		6-month ded June 30 2004	%
Operating commercial centers Hotels operation and management Sale of medical systems Sale of goods Lease of assets Total revenues	96,664 121,232 33,922 4,787 6,609 263,214	45 13 2 3	195,851 109,279 17,218 - 6,606 328,954	60 33 5 - 2
	2005		3-month ded June 30 2004	엉
Operating commercial centers Hotels operation and management Sale of medical systems Sale of goods Lease of assets Total revenues	44,827 66,689 24,307 4,787 3,304 143,914	47 17 3 2	100,205 57,192 11,705 - 3,326 172,428	58 33 7 - 2 100
			welve-month ded Dec 31 %	
Operating commercial centers Hotels operation and management Sale of medical systems Sale of goods		311,893 218,365 44,049	53 37 8	
Lease of assets Total revenues		13,238 587,545	2 100	

The breakdown of gross profit by sector of activity is presented in the following table (in NIS thousands):

	For the 6-month period ended June 30			
	2005	%	2004	%
Operating commercial centers	31,497	33	81,045	41
Hotels operation and management	12,310	10	12,475	11
Sale of medical systems	25 <b>,</b> 575	75	14,488	84
Goods sold	3,134	65	_	_
Lease of assets	5 <b>,</b> 095	77	4,971	75
Total gross profit	77,611	29	112,979	34

For the 3-month

	period ended June 30			
	2005	olo	2004	ଚ
Operating commercial centers	14,475	32	40,188	40
Hotels operation and management	8,782	13	8,607	15
Sale of medical systems	18,121	75	10,048	86
Goods sold	3,134	65	_	_
Lease of assets	2,549	77	2,548	77
Total gross profit	47,061	33	61,391	36
		For the tw	elve-month	
		For the tw period end		
		period end 2004	led Dec 31 %	
Operating commercial centers		period end 2004 112,113	led Dec 31 %	
Hotels operation and management		period end 2004 112,113 17,271	ded Dec 31 % 36 8	
		period end 2004 112,113	ded Dec 31 % 36 8	
Hotels operation and management		period end 2004 112,113 17,271	ded Dec 31 % 36 8	
Hotels operation and management Sale of medical systems		period end 2004 112,113 17,271	36 8 78	

The percentages in the above table refer to gross margins (gross profit as a percentage of the revenue in each respective sector).

The decrease in revenues for the three-month period ended on June 30, 2005, compared to the corresponding period of the previous year, is due to: (i) the exclusion of the activities of the 12 Hungarian shopping centers sold to Klepierre Group at the beginning of the third quarter of 2004; and (ii) the exclusion of the four additional shopping centers in Hungary sold to Dawnay Day Group at the beginning of the second quarter of 2005.

The consolidated net financial expenses for the three-month period ended June 30, 2005 totaled NIS 31.8 million (US \$7.0 million), compared with a net financial expenses of NIS 74.5 million in the corresponding period of 2004. This substantial decrease results from a combination of the following factors:

- 1. During the second quarter of 2005 the Company recorded financial income of NIS 10.3 million (US\$ 2.3 million) from derivative financial instrument transactions, compared to expenses of NIS 41.6 million from in the corresponding period of the previous year.
- 2. Financial expenses in the three-month period ended June 30, 2005, have increased by NIS 9.2 million (US \$2.0 million), net, mainly as a result of (i) a reduction in the amount of outstanding bank loans in Plaza Centers due to the realization of the 16 shopping centers in 2004 and 2005, on one hand; and on the other hand (ii) an increase in volume of outstanding loans granted to operating companies mainly in the hotel business, with the addition of the negative effect of exchange rate differences, mainly NIS against the US Dollar (4.8%).

Other net expenses for the three-month period ended June 30, 2005 was NIS 22.1 million (US \$4.8 million), which resulted primarily from a provision for impairment loss expected on EMI's investment in Vcon Telecommunication Ltd., and a provision for a loss that may result from decrease in EMI's shareholding in Elscint, assuming realization of Elsicnt's employees stock. The latter provision was recorded according to Israeli GAAP, as in effect through the end of 2005 (non-US GAAP), notwithstanding that the loss covered therein may not materialize, in the event EMI's proposed merger with Elscint is concluded.

In the second quarter of 2005, EMI recorded a deferred tax asset, in the amount of NIS 14.1 million (US \$3.1 million), in respect of temporary differences arising from investments in its subsidiaries since following the 2005 Klepierre transactions, as concluded in July 2005, the utilization of such temporary differences against taxable profit in the foreseeable future, became initially probable.

The basic net loss per share for the three-month period ending June 30, 2005, was NIS 1.4 per share (US \$0.3 per share).

EMI is a subsidiary of Europe Israel (M.M.S.) Ltd. EMI's activities are divided into three principal fields: (i) ownership, operation, management, acquisition, expansion and development of commercial and entertainment malls in Europe, primarily in Eastern and Central Europe; (ii) ownership, operation, leasing, management, acquisition, expansion and development of hotels in major European cities and ownership, operation and management of a commercial and entertainment mall in Israel through its subsidiary, Elscint Ltd.; and (iii) research and development in the image guided focused ultrasound activities through its subsidiary, InSightec - Image Guided Treatment Ltd.

This press release does not constitute an offer of any securities for sale. Before making any voting or investment decision, investors are urged to read the joint proxy statement/prospectus regarding the proposed merger between EMI and Elscint and any other relevant documents carefully in their entirety when they become available because they would contain important information about the proposed transaction. Any final joint proxy statement/prospectus would be mailed to EMI's and Elscint's shareholders. The registration statement containing the joint proxy statement/prospectus and other documents are available free of charge at the Securities and Exchange Commission's Internet site (http://www.sec.gov).

EMI, Elscint and their respective directors and executive officers and other members of management and employees may be deemed to be participants in the solicitation of proxies in respect of a proposed transaction. Information regarding EMI's directors and executive officers is available in EMI's Annual Report for the Fiscal Year Ended December 31, 2004, which was filed with the Securities and Exchange Commission on June 30, 2005. Information regarding Elscint's directors and executive officers is available in Elscint's Annual Report for the Fiscal Year Ended December 31, 2004, which was filed with the Securities and Exchange Commission on June 30, 2005 and as amended and filed with the Securities and Exchange Commission on July 14, 2005. Information regarding persons who may, under the rules of the Securities and Exchange Commission, be considered participants in a solicitation of EMI and Elscint shareholders in connection with a proposed transaction is set forth in the joint proxy statement/prospectus filed with the Securities and Exchange Commission.

Any forward looking statements with respect to EMI's business, financial condition and results of operations included in this release are subject to risks and uncertainties that could cause actual results to differ materially from those contemplated in such forward looking statements, including, but not limited to, product demand, pricing, market acceptance, changing economic conditions, risks in product and technology development and the effect of EMI's accounting policies, the risk that the Klepierre transactions are not consummated, risks related to the proposed merger of EMI and Elscint such as a failure to successfully integrate the two companies or realize the expected benefits from the proposed merger, as well as certain other risk factors which are detailed from time to time in EMI's filings with the Securities and Exchange Commission including, without limitation, EMI's Form F-4 Registration Statement filed with the Securities and Exchange Commission on September 1, 2005 and Form 20-F Annual Report for the fiscal year ended December 31, 2004, filed with the

Securities and Exchange Commission on June 30, 2005.

Company Contact:

----
Marc Lavine, Adv.

Elbit Medical Imaging Ltd.

011-972-3-608-6011

mlavine@europe-israel.com

-----
Investor Contact:

-----
Kathy Price

The Anne McBride Company

1-212-983-1702 x212

kprice@annemcbride.com

# ELBIT MEDICAL IMAGING LTD. CONSOLIDATED BALANCE SHEETS

	Jun	June 30		
		2004	2004	
		in thousands		
Current Assets Cash and cash equivalents Short-term deposits and investments Trade accounts receivable Receivables and other debit balances Inventories	101,689 16,299	128,343 315,460 46,648 79,298 6,894 576,643	345,745 278,021 39,102 66,140 7,331  736,339	
Long-Term Investments and Receivables Long-term deposits, debentures, loans and receivables Investments in investees and other companies	102,135 56,777  158,912	106,527 123,806  230,333	113,785 71,608  185,393	
Fixed Assets	3,483,196	4,807,211	3,527,988	
Other Assets and Deferred Expenses		77 <b>,</b> 034	55 <b>,</b> 859	
Assets Related to Discontinuing Operations	13,110	14,760	14,700	
	4,363,650 =====	5,705,981 ======	4,520,279 ======	
Current Liabilities Short-term credits Suppliers and service providers	633,744 83,355	1,052,344 97,307	536,937 74,358	

Payables and other credit balances	153 <b>,</b> 786	143,977	183,446
		1,293,628	794,741
Long-Term Liabilities	2,365,790	2,899,056	2,418,897
Liabilities Related to Discontinuing Operations	71,168	79 <b>,</b> 544	71 <b>,</b> 986
Convertible debentures	61,839		
Minority Interest	404,939	460 <b>,</b> 651	430 <b>,</b> 687
Shareholders' Equity	589 <b>,</b> 029	973 <b>,</b> 102	803 <b>,</b> 968
	4,363,650	5,705,981 ======	4,520,279

# ELBIT MEDICAL IMAGING LTD. CONSOLIDATED STATEMENT OF OPERATIONS

	Six months ended June 30		Three months ended June 30	
	2005	2004	2005	
	NIS in thousands			
_				
Revenues Commercial center operations Hotels operations and	96,664	195,851	44,827	100,205
management	121,232	109,279	66,689	57 <b>,</b> 192
Sale of medical systems	·	•	24,307	•
Sales of goods	•		4,787	
Lease of assets		6,606	3,304	
	263,214			
Costs of revenues				
Commercial center operations Hotels operations and	65,167	114,806	30,352	60,017
management	108,922	96,804	57 <b>,</b> 907	48,585
Sale of medical systems	8,347	2,730	6,186	1,657
Cost of goods sold	1,653		1,653	
				_

Lease of assets	1,514	1,635	755	778
	185,603	215,975	96,853	111,037
Gross profit	77,611	112,979	47,061	61,391
Project initiation expenses Research and development	8,948	359	3,319	182
expenses, net	26,657	21,095	15,098	9,108
Marketing and selling expenses	17,641	23,673	11,678	13,352
General and administrative expenses	49,404	39,665	23,436	20,056
	102,650	84,792 	53,531 	42,698 
Operating profit(loss) before				
financial expenses, net	(25,039)	28,187	(6,470)	18,693
Financial expenses, net	(64,560)	(27,097)	(31,788)	(74,488)
Operating profit(loss) after				
financial expenses, net	(89,599)	1,090	(38, 258)	(55 <b>,</b> 795)
Other income (expenses), net	5,222	(15 <b>,</b> 396)	(22,113)	(282)
-				
Profit (loss) before income	(04 277)	(14 206)	(60 271)	(5.6.077)
taxes	(84,377)	(14,306)	(60,371)	(56,077)
Income taxes (tax benefits)	(15,774) 	17 <b>,</b> 089	(16,567) 	1,814 
Profit (loss) after income				
taxes Share in results of	(68,603)	(31,395)	(43,804)	(57,891)
associated companies, net	(5,241)	(8,276)	(3,096)	(4,930)
Minority interest in results of subsidiaries, net	34,539	14,661	17,418	6 <b>,</b> 794
substituaties, met			17,410	
Profit (loss) from continuing operation	(39, 305)	(25,010)	(29,482)	(56,027)
Profit (loss) from discontinuing operation, net	(1,877)	848	(1,334)	1,580
Cumulative effect of accounting change at the beginning of	<b>(= / -</b> · · · /		(=, = = -,	_,
the year	(605)			
Net income (loss)	(41,787) =====	(24,162) =====	(30,816) =====	(54,447) ======
Earnings (loss) per share -				
(in NIS) Basic earnings (loss) per share:				
From continuing operation	(1.78)	(1.12)	(1.34)	(2.51)
From discontinuing operation	(0.09)	0.04	(0.06)	0.07
Cumulative effect				
of accounting change at the				
beginning of the year	(0.03)			
Basic earnings (loss) per share	(1.90)	(1.08)	(1.40)	(2.44)
Diluted earnings (loss) per share	====== (1.90)	====== (1.08)	====== (1.40)	(2.44)
ziraca carmingo (1000) per unare				